Perimeter Provides Update on Canada Postal Strike and Mailing of the Company's 2024 Annual General Meeting Materials

TORONTO and DALLAS, Dec. 3, 2024 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, wishes to notify shareholders that in case of disruption due to the ongoing Canada Post strike, the Company's meeting materials (the "Meeting Materials") for the Company's upcoming annual general meeting to be held on December 12, 2024 at 1:00 p.m. (Toronto Time) (the "Meeting"), may be viewed on the Company's SEDAR+ profile at www.sedarplus.ca and are also available electronically on the Company's website at www.perimetermed.com.

The Company has delivered the completed Meeting Materials to the appropriate parties for mailing to registered and unregistered shareholders prior to the Meeting.  However, due to the postal strike, it is possible that the Meeting Materials will not be delivered to shareholders prior to the Meeting.  Shareholders will still be able to vote their shares either directly or by proxy, or indirectly via their intermediary. Registered and beneficial shareholders who have not received their Meeting Materials, including the proxy, can direct requests for copies of the Meeting Materials to Stephen Kilmer, Investor Relations, at the contact details below. The Company will provide copies of the Meeting Materials by email to each shareholder who requests them while the strike is ongoing, at no charge.

If you are a registered shareholder, please contact Computershare Investor Services Inc. at 1-800-564-6253 (toll free within North America) or 1-514-982-7555 to obtain your proxy form control number to cast your vote for the upcoming Meeting.

If you hold shares through an intermediary such as a brokerage firm, please contact your intermediary directly for a copy of the proxy form and instructions for voting.

The Company's annual financial statements and related management discussion and analysis, as well as interim financial statements and related management discussion and analysis are available on the Company's SEDAR+ profile and the Company's website as noted above.

About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTC: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit www.perimetermed.com/disclosures.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, statements regarding the timing of the annual meeting, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023, which is available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

SOURCE Perimeter Medical Imaging AI Inc.

Contacts: Stephen Kilmer, Investor Relations, Direct: 647-872-4849, Email: [email protected]; Adrian Mendes, Chief Executive Officer, Toll-free: 888-988-7465 (PINK), Email: [email protected]